{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T08:23:37Z","timestamp":1792225417672,"version":"4.4.0"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2024,1,16]],"date-time":"2024-01-16T00:00:00Z","timestamp":1705363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,1,16]],"date-time":"2024-01-16T00:00:00Z","timestamp":1705363200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2024,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Despite recent refinements in the diagnostic and prognostic assessment of\n                    <jats:italic>CEBPA<\/jats:italic>\n                    mutations in AML, several questions remain open, i.e. implications of different types of basic region leucin zipper (bZIP) mutations, the role of co-mutations and the allelic state. Using pooled primary data analysis on 1010\n                    <jats:italic>CEBPA<\/jats:italic>\n                    -mutant adult AML patients, a comparison was performed taking into account the type of mutation (bZIP: either typical in-frame insertion\/deletion (InDel) mutations (bZIP\n                    <jats:sup>InDel<\/jats:sup>\n                    ), frameshift InDel or nonsense mutations inducing translational stop (bZIP\n                    <jats:sup>STOP<\/jats:sup>\n                    ) or single base-pair missense alterations (bZIP\n                    <jats:sup>ms<\/jats:sup>\n                    ), and transcription activation domain (TAD) mutations) and the allelic state (single (sm\n                    <jats:italic>CEBPA<\/jats:italic>\n                    ) vs. double mutant (dm\n                    <jats:italic>CEBPA<\/jats:italic>\n                    )). Only bZIP\n                    <jats:sup>InDel<\/jats:sup>\n                    patients had significantly higher rates of complete remission and longer relapse free and overall survival (OS) compared with all other\n                    <jats:italic>CEBPA-<\/jats:italic>\n                    mutant subgroups. Moreover, co-mutations in bZIP\n                    <jats:sup>InDel<\/jats:sup>\n                    patients (e.g.\n                    <jats:italic>GATA2<\/jats:italic>\n                    ,\n                    <jats:italic>FLT3<\/jats:italic>\n                    ,\n                    <jats:italic>WT1<\/jats:italic>\n                    as well as ELN2022 adverse risk aberrations) had no independent impact on OS, whereas in non-bZIP\n                    <jats:sup>InDel<\/jats:sup>\n                    patients, grouping according to ELN2022 recommendations added significant prognostic information. In conclusion, these results demonstrate bZIP\n                    <jats:sup>InDel<\/jats:sup>\n                    mutations to be the major independent determinant of outcome in\n                    <jats:italic>CEBPA<\/jats:italic>\n                    -mutant AML, thereby refining current classifications according to WHO (including all dm\n                    <jats:italic>CEBPA<\/jats:italic>\n                    and sm\n                    <jats:italic>CEBPA<\/jats:italic>\n                    bZIP) as well as ELN2022 and ICC recommendations (including\n                    <jats:italic>CEBPA<\/jats:italic>\n                    bZIP\n                    <jats:sup>ms<\/jats:sup>\n                    ).\n                  <\/jats:p>","DOI":"10.1038\/s41375-024-02140-x","type":"journal-article","created":{"date-parts":[[2024,1,16]],"date-time":"2024-01-16T08:02:17Z","timestamp":1705392137000},"page":"281-290","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":44,"title":["Prognostic impact of CEBPA mutational subgroups in adult AML"],"prefix":"10.1038","volume":"38","author":[{"given":"Julia-Annabell","family":"Georgi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0271-4894","authenticated-orcid":false,"given":"Sebastian","family":"Stasik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Kramer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manja","family":"Meggendorfer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"R\u00f6llig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Torsten","family":"Haferlach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8857-9461","authenticated-orcid":false,"given":"Peter","family":"Valk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Linch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9615-9432","authenticated-orcid":false,"given":"Tobias","family":"Herold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3927-1022","authenticated-orcid":false,"given":"Nicolas","family":"Duployez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franziska","family":"Taube","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan Moritz","family":"Middeke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1863-3239","authenticated-orcid":false,"given":"Uwe","family":"Platzbecker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hubert","family":"Serve","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0748-834X","authenticated-orcid":false,"given":"Claudia D.","family":"Baldus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7166-5232","authenticated-orcid":false,"given":"Carsten","family":"Muller-Tidow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6333-5049","authenticated-orcid":false,"given":"Claudia","family":"Haferlach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Koch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfgang E.","family":"Berdel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2273-5502","authenticated-orcid":false,"given":"Bernhard J.","family":"Woermann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Utz","family":"Krug","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6528-2078","authenticated-orcid":false,"given":"Jan","family":"Braess","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfgang","family":"Hiddemann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5139-4957","authenticated-orcid":false,"given":"Karsten","family":"Spiekermann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma L.","family":"Boertjes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert K.","family":"Hills","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan","family":"Burnett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerhard","family":"Ehninger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3920-7490","authenticated-orcid":false,"given":"Klaus","family":"Metzeler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maja","family":"Rothenberg-Thurley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annika","family":"Dufour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Herv\u00e9","family":"Dombret","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cecile","family":"Pautas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claude","family":"Preudhomme","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2808-4843","authenticated-orcid":false,"given":"Laurene","family":"Fenwarth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Bornh\u00e4user","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0103-1787","authenticated-orcid":false,"given":"Rosemary","family":"Gale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1241-2048","authenticated-orcid":false,"given":"Christian","family":"Thiede","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,1,16]]},"reference":[{"key":"2140_CR1","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1038\/85820","volume":"27","author":"T Pabst","year":"2001","unstructured":"Pabst T, Mueller BU, Zhang P, Radomska HS, Narravula S, Schnittger S, et al. Dominant-negative mutations of CEBPA, encoding CCAAT\/enhancer binding protein-alpha (C\/EBPalpha), in acute myeloid leukemia. Nat Genet. 2001;27:263\u201370.","journal-title":"Nat Genet"},{"key":"2140_CR2","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1111\/bjh.16534","volume":"190","author":"AS Wilhelmson","year":"2020","unstructured":"Wilhelmson AS, Porse BT. CCAAT enhancer binding protein alpha (CEBPA) biallelic acute myeloid leukaemia: cooperating lesions, molecular mechanisms and clinical relevance. Br J Haematol. 2020;190:495\u2013507.","journal-title":"Br J Haematol"},{"key":"2140_CR3","doi-asserted-by":"publisher","first-page":"2717","DOI":"10.1182\/blood-2002-03-0990","volume":"100","author":"C Preudhomme","year":"2002","unstructured":"Preudhomme C, Sagot C, Boissel N, Cayuela JM, Tigaud I, de Botton S, et al. Favorable prognostic significance of CEBPA mutations in patients with de novo acute myeloid leukemia: a study from the Acute Leukemia French Association (ALFA). Blood. 2002;100:2717\u201323.","journal-title":"Blood"},{"key":"2140_CR4","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1038\/sj.thj.6200216","volume":"4","author":"S Barjesteh van Waalwijk van Doorn-Kh","year":"2003","unstructured":"Barjesteh van Waalwijk van Doorn-Khosrovani S, Erpelinck C, Meijer J, van Oosterhoud S, van Putten WL, et al. Biallelic mutations in the CEBPA gene and low CEBPA expression levels as prognostic markers in intermediate-risk AML. Hematol J. 2003;4:31\u201340.","journal-title":"Hematol J"},{"key":"2140_CR5","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1200\/JCO.2004.06.060","volume":"22","author":"S Fr\u00f6hling","year":"2004","unstructured":"Fr\u00f6hling S, Schlenk RF, Stolze I, Bihlmayr J, Benner A, Kreitmeier S, et al. CEBPA mutations in younger adults with acute myeloid leukemia and normal cytogenetics: prognostic relevance and analysis of cooperating mutations. J Clin Oncol. 2004;22:624\u201333.","journal-title":"J Clin Oncol"},{"key":"2140_CR6","doi-asserted-by":"publisher","first-page":"1416","DOI":"10.1158\/1078-0432.CCR-04-1552","volume":"11","author":"M Bienz","year":"2005","unstructured":"Bienz M, Ludwig M, Leibundgut EO, Mueller BU, Ratschiller D, Solenthaler M, et al. Risk assessment in patients with acute myeloid leukemia and a normal karyotype. Clin Cancer Res. 2005;11:1416\u201324.","journal-title":"Clin Cancer Res"},{"key":"2140_CR7","doi-asserted-by":"publisher","first-page":"1909","DOI":"10.1056\/NEJMoa074306","volume":"358","author":"RF Schlenk","year":"2008","unstructured":"Schlenk RF, D\u00f6hner K, Krauter J, Fr\u00f6hling S, Corbacioglu A, Bullinger L, et al. Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia. N Engl J Med. 2008;358:1909\u201318.","journal-title":"N Engl J Med"},{"key":"2140_CR8","doi-asserted-by":"publisher","first-page":"5303","DOI":"10.1158\/1078-0432.CCR-08-2941","volume":"15","author":"T Pabst","year":"2009","unstructured":"Pabst T, Mueller BU. Complexity of CEBPA dysregulation in human acute myeloid leukemia. Clin Cancer Res. 2009;15:5303\u20137.","journal-title":"Clin Cancer Res"},{"key":"2140_CR9","doi-asserted-by":"publisher","first-page":"3088","DOI":"10.1182\/blood-2008-09-179895","volume":"113","author":"BJ Wouters","year":"2009","unstructured":"Wouters BJ, L\u00f6wenberg B, Erpelinck-Verschueren CA, van Putten WL, Valk PJ, Delwel R. Double CEBPA mutations, but not single CEBPA mutations, define a subgroup of acute myeloid leukemia with a distinctive gene expression profile that is uniquely associated with a favorable outcome. Blood. 2009;113:3088\u201391.","journal-title":"Blood"},{"key":"2140_CR10","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1200\/JCO.2008.21.6010","volume":"28","author":"A Dufour","year":"2010","unstructured":"Dufour A, Schneider F, Metzeler KH, Hoster E, Schneider S, Zellmeier E, et al. Acute myeloid leukemia with biallelic CEBPA gene mutations and normal karyotype represents a distinct genetic entity associated with a favorable clinical outcome. J Clin Oncol. 2010;28:570\u20137.","journal-title":"J Clin Oncol"},{"key":"2140_CR11","doi-asserted-by":"publisher","first-page":"2739","DOI":"10.1200\/JCO.2009.26.2501","volume":"28","author":"CL Green","year":"2010","unstructured":"Green CL, Koo KK, Hills RK, Burnett AK, Linch DC, Gale RE. Prognostic significance of CEBPA mutations in a large cohort of younger adult patients with acute myeloid leukemia: impact of double CEBPA mutations and the interaction with FLT3 and NPM1 mutations. J Clin Oncol. 2010;28:2739\u201347.","journal-title":"J Clin Oncol"},{"key":"2140_CR12","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1182\/blood-2011-02-334748","volume":"118","author":"V Rockova","year":"2011","unstructured":"Rockova V, Abbas S, Wouters BJ, Erpelinck CA, Beverloo HB, Delwel R, et al. Risk stratification of intermediate-risk acute myeloid leukemia: integrative analysis of a multitude of gene mutation and gene expression markers. Blood. 2011;118:1069\u201376.","journal-title":"Blood"},{"key":"2140_CR13","doi-asserted-by":"publisher","first-page":"2469","DOI":"10.1182\/blood-2010-09-307280","volume":"117","author":"E Taskesen","year":"2011","unstructured":"Taskesen E, Bullinger L, Corbacioglu A, Sanders MA, Erpelinck CA, Wouters BJ, et al. Prognostic impact, concurrent genetic mutations, and gene expression features of AML with CEBPA mutations in a cohort of 1182 cytogenetically normal AML patients: further evidence for CEBPA double mutant AML as a distinctive disease entity. Blood. 2011;117:2469\u201375.","journal-title":"Blood"},{"key":"2140_CR14","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1038\/leu.2013.273","volume":"28","author":"A Fasan","year":"2014","unstructured":"Fasan A, Haferlach C, Alpermann T, Jeromin S, Grossmann V, Eder C, et al. The role of different genetic subtypes of CEBPA mutated AML. Leukemia. 2014;28:794\u2013803.","journal-title":"Leukemia"},{"key":"2140_CR15","doi-asserted-by":"crossref","unstructured":"Tarlock K, Lamble A, Wang J, Gerbing RB, Ries RE, Loken MR, et al. CEBPA bZip mutations are associated with favorable prognosis in de novo AML: a report from the children\u2019s oncology group. Blood. 2021;138:1137\u201347.","DOI":"10.1182\/blood.2020009652"},{"key":"2140_CR16","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1182\/blood.2020009680","volume":"139","author":"F Taube","year":"2022","unstructured":"Taube F, Georgi JA, Kramer M, Stasik S, Middeke JM, R\u00f6llig C, et al. CEBPA mutations in 4708 patients with acute myeloid leukemia: differential impact of bZIP and TAD mutations on outcome. Blood. 2022;139:87\u2013103.","journal-title":"Blood"},{"key":"2140_CR17","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1182\/bloodadvances.2021004292","volume":"6","author":"S Wakita","year":"2022","unstructured":"Wakita S, Sakaguchi M, Oh I, Kako S, Toya T, Najima Y, et al. Prognostic impact of CEBPA bZIP domain mutation in acute myeloid leukemia. Blood Adv. 2022;6:238\u201347.","journal-title":"Blood Adv"},{"key":"2140_CR18","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1182\/blood.2022016867","volume":"140","author":"H D\u00f6hner","year":"2022","unstructured":"D\u00f6hner H, Wei AH, Appelbaum FR, Craddock C, DiNardo CD, Dombret H, et al. Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood. 2022;140:1345\u201377.","journal-title":"Blood"},{"key":"2140_CR19","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1182\/blood.2022015850","volume":"140","author":"DA Arber","year":"2022","unstructured":"Arber DA, Orazi A, Hasserjian RP, Borowitz MJ, Calvo KR, Kvasnicka HM, et al. International consensus classification of myeloid neoplasms and acute leukemias: integrating morphologic, clinical, and genomic data. Blood. 2022;140:1200\u201328.","journal-title":"Blood"},{"key":"2140_CR20","doi-asserted-by":"publisher","first-page":"1703","DOI":"10.1038\/s41375-022-01613-1","volume":"36","author":"JD Khoury","year":"2022","unstructured":"Khoury JD, Solary E, Abla O, Akkari Y, Alaggio R, Apperley JF, et al. The 5th edition of the World Health Organization Classification of haematolymphoid tumours: myeloid and histiocytic\/dendritic neoplasms. Leukemia. 2022;36:1703\u201319.","journal-title":"Leukemia"},{"key":"2140_CR21","first-page":"6919","volume":"13","author":"PF Johnson","year":"1993","unstructured":"Johnson PF. Identification of C\/EBP basic region residues involved in DNA sequence recognition and half-site spacing preference. Mol Cell Biol. 1993;13:6919\u201330.","journal-title":"Mol Cell Biol"},{"key":"2140_CR22","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1182\/blood-2012-01-403220","volume":"120","author":"PA Greif","year":"2012","unstructured":"Greif PA, Dufour A, Konstandin NP, Ksienzyk B, Zellmeier E, Tizazu B, et al. GATA2 zinc finger 1 mutations associated with biallelic CEBPA mutations define a unique genetic entity of acute myeloid leukemia. Blood. 2012;120:395\u2013403.","journal-title":"Blood"},{"key":"2140_CR23","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1111\/bjh.12297","volume":"161","author":"V Grossmann","year":"2013","unstructured":"Grossmann V, Haferlach C, Nadarajah N, Fasan A, Weissmann S, Roller A, et al. CEBPA double-mutated acute myeloid leukaemia harbours concomitant molecular mutations in 76\u00b78% of cases with TET2 and GATA2 alterations impacting prognosis. Br J Haematol. 2013;161:649\u201358.","journal-title":"Br J Haematol"},{"key":"2140_CR24","doi-asserted-by":"publisher","first-page":"E93","DOI":"10.1002\/ajh.23949","volume":"90","author":"A Marceau-Renaut","year":"2015","unstructured":"Marceau-Renaut A, Guihard S, Castaigne S, Dombret H, Preudhomme C, Cheok M. Classification of CEBPA mutated acute myeloid leukemia by GATA2 mutations. Am J Hematol. 2015;90:E93\u20134.","journal-title":"Am J Hematol"},{"key":"2140_CR25","doi-asserted-by":"publisher","first-page":"1641","DOI":"10.1007\/s00277-019-03699-7","volume":"98","author":"L Su","year":"2019","unstructured":"Su L, Gao S, Tan Y, Lin H, Liu X, Liu S, et al. CSF3R mutations were associated with an unfavorable prognosis in patients with acute myeloid leukemia with CEBPA double mutations. Ann Hematol. 2019;98:1641\u20136.","journal-title":"Ann Hematol"},{"key":"2140_CR26","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1038\/s41417-019-0133-7","volume":"27","author":"Y Zhang","year":"2020","unstructured":"Zhang Y, Wang F, Chen X, Zhang Y, Wang M, Liu H, et al. Companion gene mutations and their clinical significance in AML with double mutant CEBPA. Cancer Gene Ther. 2020;27:599\u2013606.","journal-title":"Cancer Gene Ther"},{"key":"2140_CR27","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1007\/s12185-022-03322-y","volume":"116","author":"J He","year":"2022","unstructured":"He J, Liu J, Shen H, Wang Z, Cao L, Wu P, et al. Companion gene mutations and their clinical significance in AML with double or single mutant CEBPA. Int J Hematol. 2022;116:71\u201380.","journal-title":"Int J Hematol"},{"key":"2140_CR28","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1080\/16078454.2022.2103964","volume":"27","author":"T Wang","year":"2022","unstructured":"Wang T, Hua H, Wang Z, Wang B, Cao L, Qin W, et al. Frequency and clinical impact of WT1 mutations in the context of CEBPA-mutated acute myeloid leukemia. Hematology. 2022;27:994\u20131002.","journal-title":"Hematology"},{"key":"2140_CR29","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1007\/s00277-012-1423-4","volume":"91","author":"A Dufour","year":"2012","unstructured":"Dufour A, Schneider F, Hoster E, Benthaus T, Ksienzyk B, Schneider S, et al. Monoallelic CEBPA mutations in normal karyotype acute myeloid leukemia: independent favorable prognostic factor within NPM1 mutated patients. Ann Hematol. 2012;91:1051\u201363.","journal-title":"Ann Hematol"},{"key":"2140_CR30","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1038\/leu.2012.174","volume":"27","author":"A Fasan","year":"2013","unstructured":"Fasan A, Eder C, Haferlach C, Grossmann V, Kohlmann A, Dicker F, et al. GATA2 mutations are frequent in intermediate-risk karyotype AML with biallelic CEBPA mutations and are associated with favorable prognosis. Leukemia. 2013;27:482\u20135.","journal-title":"Leukemia"},{"key":"2140_CR31","doi-asserted-by":"publisher","first-page":"2724","DOI":"10.1182\/bloodadvances.2018016840","volume":"2","author":"NP Konstandin","year":"2018","unstructured":"Konstandin NP, Pastore F, Herold T, Dufour A, Rothenberg-Thurley M, Hinrichsen T, et al. Genetic heterogeneity of cytogenetically normal AML with mutations of CEBPA. Blood Adv. 2018;2:2724\u201331.","journal-title":"Blood Adv"},{"key":"2140_CR32","doi-asserted-by":"publisher","first-page":"e510","DOI":"10.3324\/haematol.2018.189043","volume":"103","author":"FM Tien","year":"2018","unstructured":"Tien FM, Hou HA, Tang JL, Kuo YY, Chen CY, Tsai CH, et al. Concomitant WT1 mutations predict poor prognosis in acute myeloid leukemia patients with double mutant CEBPA. Haematologica. 2018;103:e510\u2013e3.","journal-title":"Haematologica"},{"key":"2140_CR33","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1016\/j.bbmt.2018.11.031","volume":"25","author":"H Wang","year":"2019","unstructured":"Wang H, Chu TT, Han SY, Qi JQ, Tang YQ, Qiu HY, et al. FLT3-ITD and CEBPA mutations predict prognosis in acute myelogenous leukemia irrespective of hematopoietic stem cell transplantation. Biol Blood Marrow Transpl. 2019;25:941\u20138.","journal-title":"Biol Blood Marrow Transpl"},{"key":"2140_CR34","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-41927-x","volume":"14","author":"E Heyes","year":"2023","unstructured":"Heyes E, Wilhelmson AS, Wenzel A, Manhart G, Eder T, Schuster MB, et al. TET2 lesions enhance the aggressiveness of CEBPA-mutant acute myeloid leukemia by rebalancing GATA2 expression. Nat Commun. 2023;14:6185.","journal-title":"Nat Commun"},{"key":"2140_CR35","doi-asserted-by":"publisher","first-page":"91","DOI":"10.3324\/haematol.2017.173096","volume":"103","author":"D El-Sharkawi","year":"2018","unstructured":"El-Sharkawi D, Sproul D, Allen CG, Feber A, Wright M, Hills RK, et al. Variable outcome and methylation status according to CEBPA mutant type in double-mutated acute myeloid leukemia patients and the possible implications for treatment. Haematologica. 2018;103:91\u2013100.","journal-title":"Haematologica"},{"key":"2140_CR36","doi-asserted-by":"publisher","first-page":"244","DOI":"10.2174\/138920309788452164","volume":"10","author":"M Miller","year":"2009","unstructured":"Miller M. The importance of being flexible: the case of basic region leucine zipper transcriptional regulators. Curr Protein Pept Sci. 2009;10:244\u201369.","journal-title":"Curr Protein Pept Sci"},{"key":"2140_CR37","doi-asserted-by":"publisher","first-page":"102686","DOI":"10.1016\/j.isci.2021.102686","volume":"24","author":"E Ramberger","year":"2021","unstructured":"Ramberger E, Sapozhnikova V, Kowenz-Leutz E, Zimmermann K, Nicot N, Nazarov PV, et al. PRISMA and BioID disclose a motifs-based interactome of the intrinsically disordered transcription factor C\/EBP\u03b1. iScience. 2021;24:102686.","journal-title":"iScience"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41375-024-02140-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-024-02140-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-024-02140-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,8]],"date-time":"2024-02-08T09:04:15Z","timestamp":1707383055000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41375-024-02140-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,16]]},"references-count":37,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,2]]}},"alternative-id":["2140"],"URL":"https:\/\/doi.org\/10.1038\/s41375-024-02140-x","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,16]]},"assertion":[{"value":"30 October 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 December 2023","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 January 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 January 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"C.T. is CEO and co-owner of AgenDix GmbH; all other authors have nothing to disclose.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}